Selected article for: "preferred choice and treatment preferred choice"
Author: Latika Gupta; Durga Misra; Vishwesh Agarwal; Suma Balan; Vikas Agarwal
Title: Management of rheumatic diseases in the times of COVID-19 pandemic- perspectives of rheumatology practitioners from India
  • Document date: 2020_4_7
    • ID: 2kkw9nwa_7
    Snippet: Hydroxychloroquine was the preferred choice (81.9%) for the treatment of COVID-19 followed by protease inhibitors (22.1%) and intravenous immunoglobulin (8.1%)......
    Document: Hydroxychloroquine was the preferred choice (81.9%) for the treatment of COVID-19 followed by protease inhibitors (22.1%) and intravenous immunoglobulin (8.1%).

    Search related documents: